Formulation and method for the prevention and/or treatment of hangover symptoms

Abstract

A formulation and a method for treating, preventing, ameliorating or alleviating in a patient the symptoms of hangover, or of veisalgia, associated with a bout of excessive alcohol consumption are disclosed. More specifically, a formulation comprising L-cysteine, thiamine and pyridoxine and a method for treating, preventing, ameliorating or alleviating in a patient one or more of the symptoms of nausea, headache, diminished concentration, malaise and/or tiredness, and a desire to consume greasy and/or fatty and/or oily foods, associated with a bout of excessive alcohol consumption are disclosed.

1 - 68 . (canceled) 
     
     
         69 . A formulation for treating, preventing, ameliorating or alleviating in a patient symptoms of hangover, or of veisalgia, associated with a bout of excessive alcohol consumption, the formulation comprising:
 a therapeutically effective amount of L-cysteine;   a therapeutically effective amount of thiamine; and   a therapeutically effective amount of pyridoxine.   
     
     
         70 . The formulation of  claim 69 , further comprising a therapeutically effective amount of ascorbic acid. 
     
     
         71 . The formulation of  claim 70 , further comprising a therapeutically effective amount of glucose. 
     
     
         72 . The formulation of  claim 69 , wherein the L-cysteine is included in the range 20% to 40% w/w, or of approximately 20% to 40% w/w. 
     
     
         73 . The formulation of  claim 72 , wherein the L-cysteine is included at 30.77% w/w, or approximately 30.77% w/w. 
     
     
         74 . The formulation of  claim 69 , wherein the thiamine is included in the range 0.3% to 4.9% w/w, or of approximately 0.3% to 4.9% w/w. 
     
     
         75 . The formulation of  claim 74 , wherein the thiamine is included at 2.56% w/w, or approximately 2.56% w/w. 
     
     
         76 . The formulation of  claim 69 , wherein the pyridoxine is included in the range 3.0% to 7.26% w/w, or of approximately 3.0% to 7.26% w/w. 
     
     
         77 . The formulation of  claim 76 , wherein the pyridoxine is included at 5.13% w/w, or approximately 5.13% w/w. 
     
     
         78 . The formulation of  claim 70 , wherein the ascorbic acid is included in the range 20% to 40% w/w, or of approximately 20% to 40% w/w. 
     
     
         79 . The formulation of  claim 78 , wherein the ascorbic is included at 30.77% w/w, or approximately 30.77%. 
     
     
         80 . The formulation of  claim 71 , wherein the glucose is included in the range 20% to 40% w/w, or of approximately 20% to 40% w/w. 
     
     
         81 . The formulation of  claim 80 , wherein the glucose is included at 30.77% w/w, or approximately 30.77%. 
     
     
         82 . The formulation of  claim 69 , wherein L-cysteine is provided in crystalline form or as an anhydrous hydrochloride salt, thiamine and pyridoxine is provided in crystalline form or as a hydrochloride salt, pyridoxine is provided in crystalline form, ascorbic acid is provided in crystalline form, glucose is provided in crystalline form or as dextrose monohydrate. 
     
     
         83 . The formulation of  claim 71 , wherein the % w/w for each of the active ingredients equates to the following quantities, or approximate quantities:
 L-cysteine—600 mg   Thiamine—50 mg   Pyridoxine—100 mg   Ascorbic acid—600 mg   Glucose—600 mg   
     
     
         84 . A method of treating, preventing, ameliorating or alleviating in a patient symptoms of hangover, or of veisalgia, associated with a bout of excessive alcohol consumption, the method comprising:
 a. administering to the patient a first dose of the formulation of  claim 69 ; and   b. administering to the patient a second dose of the formulation of  claim 69  between 4 and 10 hours after administration of the first dose.   
     
     
         85 . The method of  claim 84 , wherein the first dose is taken immediately, or within approximately 5 to approximately 240 minutes after the last alcoholic beverage consumed during the bout. 
     
     
         86 . The method of  claim 85 , wherein the first dose is taken immediately, or within approximately 5 to approximately 180 minutes after the last alcoholic beverage consumed during the bout. 
     
     
         87 . The method of  claim 86 , wherein the first dose is taken within approximately 15 minutes to approximately 45 minutes after the last alcoholic beverage consumed during the bout. 
     
     
         88 . The method of  claim 87 , wherein the symptoms of hangover, or of veisalgia, treated, prevented, ameliorated or alleviated in a patient include one or more of the following symptoms: nausea, headache, diminished concentration, malaise and/or tiredness, and a desire to consume greasy and/or fatty and/or oily foods.